key: cord-0851701-xm6wzrpb
authors: Luzzi, José Roberto; Navarro, Roberta; Dinardo, Carla Luana
title: COVID-19: Further evidence of no transfusion transmission
date: 2020-10-07
journal: Transfus Apher Sci
DOI: 10.1016/j.transci.2020.102961
sha: bf12297d048b9056d05e14b63085b445c3027319
doc_id: 851701
cord_uid: xm6wzrpb

nan

that there is no risk of RNA-emia in asymptomatic blood donors, but the sample size was very low [1] . The other study followed-up recipients of blood products of seven donors who tested positive for SARS-CoV-2 infection 6-15 days following the donation and documented that none developed SARS-CoV-2-related symptoms [2] . Similarly, one study has reported the case of an adult donor of hematopoietic stem cells who was in the incubation period of SARS-CoV-2 infection at the moment of the collection and the recipient had no laboratorial or clinical evidences of infection [3] .

In our service, we had 5 donors who experienced COVID-19 symptoms after donation whose blood products have already been transfused to patients. The time between the donation and the COVID-19-related symptoms varied from 1-8 days. Two donors had the COVID-19 diagnosis confirmed by PCR, while 2 confirmed the infection through anti-SARS-CoV-2 immunoassays and 2 had presumptive diagnosis. There were 9 blood products derived from the donations: 6 platelet units, 1 red blood cell unit and 2 granulocyte concentrates. All but one of the 9 J o u r n a l P r e -p r o o f recipients were immunosuppressed and none presented COVID-19 related symptoms after the transfusions. Interestingly, one recipient with acute lymphoblastic leukemia was transfused with two granulocytes concentrates stemming from two donors with COVID-19 in the incubation period. This patient was critically ill, but the clinical symptoms have not worsened after the transfusion and COVID-19 RT-PCR was negative in the follow-up. Table1 displays a summary of the donors and patients evaluated in this study.

In sum, we provide here further evidence that SARS-CoV-2 infection is not transfusiontransmitted. This is very important information for transfusion services, as sheds light to the fact that testing blood donors with immunoassays to detect anti-SARS-CoV-2 antibodies is not recommended unless the goal is to provide an epidemiological overview of the infection.

SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission

Post-donation COVID-19 identification in blood donors

No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19

No funding to declare